Ampio Pharmaceuticals, Inc.  

(Public, NASDAQ:AMPE)   Watch this stock  
Find more results for ampe
4.67
0.00 (0.00%)
May 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.31 - 5.08
52 week 2.55 - 6.25
Open 5.06
Vol / Avg. 0.00/260,759.00
Mkt cap 173.22M
P/E     -
Div/yield     -
EPS -0.36
Shares 37.09M
Beta -53.84
Inst. own 21%
May 22, 2013
Ampio Pharmaceuticals Inc at UBS Global Healthcare Conference - 12:00PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -33666.56% -23186.10%
Operating margin -32688.96% -23641.52%
EBITD margin - -23516.72%
Return on average assets -65.73% -51.15%
Return on average equity -71.59% -55.75%
Employees 13 -
Carbon Disclosure Rating - -

Address

Suite 925, 5445 DTC Parkway
GREENWOOD VILLAGE, CO 80111
United States - Map
+1-720-4376500 (Phone)
+1-302-6451280 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Ampio Pharmaceuticals, Inc. (Ampio) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company is primarily focused on providing medicines to improve the health and quality of life of patients with minimal side effects. Ampio is engaged in developing pharmaceutical drugs and diagnostic products to identify, treat and prevent a range of human diseases, including metabolic disorders, eye disease, kidney disease, acute and chronic inflammation diseases and male sexual dysfunction. The Company is also focused on monetizing its sexual dysfunction portfolio and a diagnostic device. In February 2013, it announced the incorporation and initiation of operations of Luoxis Diagnostics.

Officers and directors

Michael Macaluso Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Mark D. McGregor Chief Financial Officer
Age: 71
Bio & Compensation  - Reuters
Josh Disbrow Chief Operating Officer
Age: 37
Bio & Compensation  - Reuters
David Bar-Or M.D. Chief Scientific Officer, Director
Age: 64
Bio & Compensation  - Reuters
Vaughan Lennox Clift M.D. Chief Regulatory Affairs Officer
Age: 51
Bio & Compensation  - Reuters
Philip H. Coelho Independent Director
Age: 69
Bio & Compensation  - Reuters
Richard B. Giles Independent Director
Age: 63
Bio & Compensation  - Reuters
David R. Stevens Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters